$REPL earnings report

Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update. AlphAI read Replimune Group's Fiscal second quarter 2027 filing as mixed. 2 quarters are on record below.

Fiscal second quarter 2027

AlphAI · Earnings readREPL · Fiscal second quarter 2027 · ended September 30, 2026

Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update

→Mixed quarter

TUDRIQEV entered commercial availability and management reported early account engagement and prescribing activity, while the company remained pre-revenue in the reported statements and recorded a GAAP net loss of $ (57,121) (in thousands).

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Research and development expense, three months ended September 30 (Amounts in thousands)GAAP$34.37M––
Selling, general and administrative expense, three months ended September 30 (Amounts in thousands)GAAP21.92M––
Total operating expenses, three months ended September 30 (Amounts in thousands)GAAP56.28M––
Loss from operations, three months ended September 30 (Amounts in thousands)GAAP−56.28M––
Research and development incentives, three months ended September 30 (Amounts in thousands)GAAP238K––
Investment income, three months ended September 30 (Amounts in thousands)GAAP1.88M––
Interest expense on finance lease liability, three months ended September 30 (Amounts in thousands)GAAP−502K––
Interest expense on debt obligations, three months ended September 30 (Amounts in thousands)GAAP−2.52M––
Other income (expense), net, three months ended September 30 (Amounts in thousands)GAAP67K––
Total other (expense) income, net, three months ended September 30 (Amounts in thousands)GAAP−840K––
Net loss, three months ended September 30 (Amounts in thousands)GAAP−$57.12M––
Net loss per common share, basic and diluted, three months ended September 30GAAP$ (0.54 )––
Weighted average common shares outstanding, basic and diluted, three months ended September 30other105,176,101––
Research and development expense, six months ended September 30 (Amounts in thousands)GAAP$83.64M––
Selling, general and administrative expense, six months ended September 30 (Amounts in thousands)GAAP40.88M––
Total operating expenses, six months ended September 30 (Amounts in thousands)GAAP124.5M––
Loss from operations, six months ended September 30 (Amounts in thousands)GAAP−124.5M––
Research and development incentives, six months ended September 30 (Amounts in thousands)GAAP534K––
Investment income, six months ended September 30 (Amounts in thousands)GAAP3.84M––
Interest expense on finance lease liability, six months ended September 30 (Amounts in thousands)GAAP−1.01M––
Interest expense on debt obligations, six months ended September 30 (Amounts in thousands)GAAP−5.10M––
Other income (expense), net, six months ended September 30 (Amounts in thousands)GAAP−621K––
Total other (expense) income, net, six months ended September 30 (Amounts in thousands)GAAP−2.36M––
Net loss, six months ended September 30 (Amounts in thousands)GAAP−$126.9M––
Net loss per common share, basic and diluted, six months ended September 30GAAP$ (1.26 )––
Weighted average common shares outstanding, basic and diluted, six months ended September 30other101,042,985––
Research and development stock-based compensation expense, fiscal second quarter ended September 30, 2026GAAP$4.9M––
Selling, general and administrative stock-based compensation expense, fiscal second quarter ended September 30, 2026GAAP$5.7M––
Cash, cash equivalents and short-term investments, September 30, 2026 (in thousands)GAAP$307.8M––
Working capital, September 30, 2026 (in thousands)GAAP278.5M––
Total assets, September 30, 2026 (in thousands)GAAP373.9M––
Total stockholders' equity, September 30, 2026 (in thousands)GAAP204.8M––

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

From the issuance of the condensed consolidated financial statements outlook

  • NoteExisting cash and cash equivalents will enable the Company to fund operations for greater than twelve months, including the commercialization of TUDRIQEV in advanced melanoma and for working capital and general corporate purposes.

What drove it

  • TUDRIQEV was first delivered to patients for advanced melanoma on October 6th.
  • More than 15 institutions have prescribed TUDRIQEV.
  • The company actively engaged with more than 70 percent of its initial 200 priority accounts to establish workflows and enable adoption.
  • Leading melanoma institutions placed TUDRIQEV on formulary and started treating patients.
  • Management attributed the lower research and development expense to decreases in personnel-related and other costs and direct research costs relating to the IGNYTE, ARTACUS and CERPASS studies.
  • IGNYTE-3 and the registration-directed REVEAL study remain actively enrolling.

Concerns

  • No revenue was reported in the condensed consolidated statements of operations.
  • TUDRIQEV's indication is approved under accelerated approval based on objective response rate and duration of response; continued approval may be contingent upon verification of clinical benefit in confirmatory trial(s).
  • The company reported a GAAP net loss of $ (57,121) (in thousands) for the three months ended September 30, 2026.
  • Interest expense on debt obligations was (2,523 ) (in thousands) for the three months ended September 30, 2026.
  • The company cited limited commercialization experience, confirmatory-trial execution, manufacturing, reimbursement and utilization among risks.

What to watch

  • TUDRIQEV ordering, formulary placement, payer-policy coverage and patient treatment progress following commercial availability.
  • Enrollment and future results from IGNYTE-3, whose primary endpoint is overall survival.
  • Enrollment and future results from the REVEAL Phase 2/3 trial of RP2 in metastatic uveal melanoma.
  • Cash burn related to operating activities, commercialization spending and the stated greater-than-twelve-month cash runway.
  • Execution against the company's product manufacturing goal and availability of combination therapies needed for clinical trials.

Balance sheet and cash flow

  • Cash, cash equivalents and short-term investments were $ 307,833 (in thousands) as of September 30, 2026, compared with $ 268,889 (in thousands) as of March 31, 2026.
  • The company reported approximately net $141.0 million in proceeds from its August 2026 offering of common stock and pre-funded warrants.
  • The company received $15.0 million in proceeds from long-term debt from the initial draw down on tranche 4 in September 2026.
  • Working capital was 278,482 (in thousands), total assets were 373,940 (in thousands), and total stockholders' equity was 204,778 (in thousands) as of September 30, 2026.

Analysis

Replimune reported its fiscal second quarter ended September 30, 2026 as it began the commercial launch of TUDRIQEV. The company said healthcare providers began ordering the product for next-day delivery immediately upon availability, that more than 15 institutions have prescribed it, and that it had engaged with more than 70 percent of its initial 200 priority accounts. These are early launch activity indicators rather than reported sales, as the condensed consolidated statements of operations contain no revenue line.

The expense base was lower than the prior-year quarter on the reported GAAP lines. Research and development expense was $ 34,365 (in thousands), compared with $ 57,877, and selling, general and administrative expense was 21,916, compared with 26,414. Management attributed the research and development reduction to lower personnel-related and other costs and lower direct research costs related to the IGNYTE, ARTACUS and CERPASS studies. The lower operating expense base corresponded with a net loss of $ (57,121) (in thousands), compared with $ (83,100).

Liquidity increased during the period. Cash, cash equivalents and short-term investments were $ 307,833 (in thousands) at September 30, 2026, versus $ 268,889 at March 31, 2026. Management attributed the increase to approximately net $141.0 million from the August offering of common stock and pre-funded warrants and $15.0 million from the tranche 4 debt draw, partly offset by operating cash burn. The company expects existing cash and cash equivalents to fund operations for greater than twelve months from issuance of the condensed consolidated financial statements.

The strategic focus remains commercial execution for TUDRIQEV alongside pivotal and registration-directed development work. IGNYTE-3 is actively enrolling with overall survival as its primary endpoint, while the REVEAL Phase 2/3 study of RP2 is also actively enrolling. Continued approval of TUDRIQEV may be contingent on confirmatory verification of clinical benefit, making execution of IGNYTE-3, launch uptake, payer coverage and manufacturing progress central reported watch items.

Management, verbatim

The response from physicians has been enthusiastic and both oncologists and interventional radiologists are eager to bring TUDRIQEV into their practices. They value the broad label that lets them treat patients immediately after progression on a PD-1 based therapy. We are focused on reaching as many of these patients as possible.

Sushil Patel, Ph.D., CEO of Replimune

Not in the filing

stated, not guessed
  • Revenue and revenue comparisons
  • Segment revenue and segment comparisons
  • Gross profit and gross margin
  • Operating income as a positive metric; the company reported loss from operations
  • Non-GAAP financial metrics, including non-GAAP EPS
  • Operating cash flow
  • Free cash flow
  • Cash flow statement
  • Debt balance
  • Share repurchases
  • Dividends
  • Prior-quarter comparative figures for the three-month operating-results metrics
  • Explicit percentage year-over-year or sequential changes for reported financial-statement metrics
  • The previous outlook contained no guidance for a reported metric in this quarter, only liquidity and timing statements that do not match any reported figure.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Fiscal first quarter 2027

AlphAI · Earnings readREPL · Fiscal first quarter 2027 · ended June 30, 2026

TUDRIQEV in combination with nivolumab receives FDA accelerated approval and will launch within 60 days

→Mixed quarter

The FDA accelerated approval of TUDRIQEV and a reduced net loss were important milestones, but the company reported no revenue, remains loss-making, and must execute a first commercial launch while completing the IGNYTE-3 confirmatory trial.

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Research and development expensesGAAP$49.3M––
Selling, general and administrative expensesGAAP$19M––
Total operating expensesGAAP$68.25M––
Loss from operationsGAAP−$68.25M––
Research and development incentivesGAAP$296K––
Investment incomeGAAP$1.96M––
Interest expense on finance lease liabilityGAAP−$506K––
Interest expense on debt obligationsGAAP−$2.58M––
Other (expense) income, netGAAP−$688K––
Total other (expense) income, netGAAP−$1.52M––
Net lossGAAP−$69.77M––
Net loss per common share, basic and dilutedGAAP$(0.72)––
Weighted average common shares outstanding, basic and dilutedGAAP96,864,452––
Research and development stock-based compensation expensesGAAP$3.6M––
Selling, general and administrative stock-based compensation expensesGAAP$4.1M––
Cash, cash equivalents and short-term investmentsother$195.3M––
Working capitalGAAP162.4M––
Total assetsGAAP252.4M––
Total stockholders' equityGAAP105.6M––

greater than twelve months from the issuance of the condensed consolidated financial statements outlook

  • NoteExisting cash and cash equivalents and short-term investments, as of June 30, 2026, in addition to the $141.0 million of net proceeds from the issuance of our common stock in August 2026, will enable us to fund operations for greater than twelve months from the issuance of the condensed consolidated financial statements.
  • NoteThe Company anticipates having product in the market within 60 days.
  • NoteThe IGNYTE-3 primary endpoint is expected to readout in 2030.
  • NoteREVEAL Phase 2/3 transition is expected in Q1 2027.

Capital returns

  • Replimune recently completed a $150 million financing to support commercial launch and the ongoing IGNYTE-3 confirmatory trial.
  • $141.0 million of net proceeds from the issuance of our common stock in August 2026.

What drove it

  • Research and development expenses decreased primarily due to a decrease in personnel related and other costs, as well as a decrease in direct research costs relating to the IGNYTE, ARTACUS and CERPASS studies.
  • TUDRIQEV received FDA accelerated approval in combination with nivolumab for adults with unresectable advanced cutaneous melanoma who experienced disease progression with a PD-1 antibody-based regimen.
  • The company has begun U.S. launch preparations and is completing the build out of its commercial infrastructure.
  • Michelle DiNapoli was appointed Chief Commercial Officer, effective August 18, 2026.

Concerns

  • TUDRIQEV's accelerated approval is based on objective response rate and duration of response, and continued approval may be contingent upon verification of clinical benefit in a confirmatory trial or trials.
  • The global Phase 3 IGNYTE-3 confirmatory study is actively enrolling, with its primary endpoint expected to readout in 2030.
  • The company reported a net loss of $69.8 million for the fiscal first quarter ended June 30, 2026.
  • Cash, cash equivalents and short-term investments declined to $195.3 million as of June 30, 2026 from $268.9 million as of fiscal year ended March 31, 2026.

What to watch

  • Timing of TUDRIQEV availability in the market within 60 days.
  • Execution of the commercial infrastructure buildout and launch in advanced melanoma.
  • Enrollment and eventual overall-survival readout from IGNYTE-3, expected in 2030.
  • REVEAL enrollment and the expected Phase 2/3 transition in Q1 2027.
  • Cash runway following the $141.0 million of net proceeds from the August 2026 common-stock issuance.

Balance sheet and cash flow

  • Cash, cash equivalents and short-term investments were $195.3 million as of June 30, 2026, as compared to $268.9 million as of fiscal year ended March 31, 2026.
  • The decrease in cash balance was a result of cash burn related to operating activities in advancing the company’s clinical development plans.
  • Working capital was 162,395 (in thousands) as of June 30, 2026, compared with 220,891 (in thousands) as of March 31, 2026.
  • Total assets were 252,447 (in thousands) as of June 30, 2026, compared with 332,388 (in thousands) as of March 31, 2026.
  • Total stockholders' equity was 105,645 (in thousands) as of June 30, 2026, compared with 166,160 (in thousands) as of March 31, 2026.

Analysis

Replimune entered its fiscal first quarter 2027 following FDA accelerated approval of TUDRIQEV in combination with nivolumab for adults with unresectable advanced cutaneous melanoma who progressed on a PD-1 antibody-based regimen. The company has begun U.S. launch preparations and anticipates having product in the market within 60 days. This is the central operational development in the filing and transitions the company into commercial execution.

The reported financial profile remains pre-revenue and loss-making. Net loss was $69.8 million for the fiscal first quarter ended June 30, 2026, compared with $86.7 million for the fiscal first quarter ended June 30, 2025, while net loss per common share, basic and diluted, was $(0.72), compared with $(0.95). Research and development expenses were $49.3 million compared with $57.8 million, and selling, general and administrative expenses were $19.0 million compared with $32.6 million. The company attributed lower research and development expense primarily to lower personnel related and other costs and lower direct research costs for the IGNYTE, ARTACUS and CERPASS studies.

Liquidity and financing are key to the launch and trial plan. Cash, cash equivalents and short-term investments were $195.3 million as of June 30, 2026, compared with $268.9 million as of fiscal year ended March 31, 2026. Replimune stated that the cash decrease resulted from operating cash burn associated with clinical development. The company recently completed a $150 million financing and cited $141.0 million of net proceeds from the August 2026 common-stock issuance; it expects its cash resources, including those proceeds, to fund operations for greater than twelve months from issuance of the condensed consolidated financial statements.

The principal clinical and regulatory issue is confirmation of TUDRIQEV's clinical benefit, because continued approval may be contingent on a confirmatory trial or trials. IGNYTE-3 is actively enrolling, with overall survival as its primary endpoint and an expected readout in 2030. The RP2 REVEAL study is also actively enrolling, with Phase 2/3 transition expected in Q1 2027. Investors should focus on commercial launch execution, progress in both studies, and the ability of the stated funding runway to support commercialization, working capital, general corporate purposes and the ongoing confirmatory trial.

Management, verbatim

The FDA’s approval of TUDRIQEV is a defining milestone for Replimune and, more importantly, for the patients facing advanced melanoma, where the need for safe and effective treatment options remains significant. With this approval, we are now a fully integrated biotechnology company. We are completing the build out of our commercial infrastructure to enable a successful launch and bring TUDRIQEV to patients as quickly as possible.

Sushil Patel, Ph.D., CEO of Replimune

Not in the filing

stated, not guessed
  • Total revenue
  • Revenue prior-year comparison
  • Revenue prior-quarter comparison
  • Revenue growth rates
  • Segment revenue and segment comparisons
  • Gross profit
  • Gross margin
  • Operating income
  • Non-GAAP financial metrics
  • Operating cash flow
  • Free cash flow
  • Debt balance
  • Share repurchases
  • Dividends
  • Explicit revenue guidance
  • Explicit gross-margin guidance
  • Explicit operating-expense guidance
  • Explicit tax-rate guidance
  • Previous-quarter operating-results comparisons
  • Prior outlook for comparison with reported results

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about REPL earnings dates

When is Replimune Group's next earnings date?
AlphAI has no date for REPL yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.